Gilead Sciences Plans Western China Ops Center in Chengdu
publication date: Jul 11, 2019
Gilead Sciences signed a strategic cooperation agreement with Chengdu Hi-tech Zone to develop a Western China Operation Center at the Chengdu park. Gilead is known for developing drugs for difficult-to-treat infections, especially HIV/AIDS and hepatitis C. Its first China approval came in 2017 for the hepatitis C treatment Solvadi. In China, Gilead opened a Shanghai commercial office in 2016. Currently, Gilead is conducting clinical trials of sofosbuvir/velpatasvir, the company's single-tablet treatment for HCV, at sites across China. More details....
Stock Symbol: (NSDQ: GILD)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.